These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 28295239

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. An Ex Vivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome.
    Galbusera M, Noris M, Gastoldi S, Bresin E, Mele C, Breno M, Cuccarolo P, Alberti M, Valoti E, Piras R, Donadelli R, Vivarelli M, Murer L, Pecoraro C, Ferrari E, Perna A, Benigni A, Portalupi V, Remuzzi G.
    Am J Kidney Dis; 2019 Jul; 74(1):56-72. PubMed ID: 30851964
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Eculizumab dose tapering should take into account the nonlinearity of its pharmacokinetics.
    Le Tilly O, Gatault P, Semlali S, Sberro-Soussan R, Passot C, Bertrand D, Desvignes C, Caillard S, Paintaud G, Halimi JM, Ternant D.
    Br J Clin Pharmacol; 2024 May; 90(5):1312-1321. PubMed ID: 38373846
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Optimal duration of treatment with eculizumab in atypical hemolytic uremic syndrome (aHUS)-a question to be addressed in a scientific way.
    Ariceta G.
    Pediatr Nephrol; 2019 May; 34(5):943-949. PubMed ID: 30693384
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases.
    Ardissino G, Testa S, Possenti I, Tel F, Paglialonga F, Salardi S, Tedeschi S, Belingheri M, Cugno M.
    Am J Kidney Dis; 2014 Oct; 64(4):633-7. PubMed ID: 24656451
    [Abstract] [Full Text] [Related]

  • 10. Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use.
    Wijnsma KL, Duineveld C, Wetzels JFM, van de Kar NCAJ.
    Pediatr Nephrol; 2019 Nov; 34(11):2261-2277. PubMed ID: 30402748
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Eculizumab for atypical hemolytic-uremic syndrome. How long should we maintain it?
    Naranjo Muñoz J, Garcia Garcia-Doncel A, Montero Escobar ME, Villanego Fernandez F, Millán Ortega I, Ceballos Guerrero M.
    Nefrologia (Engl Ed); 2019 Nov; 39(4):440-442. PubMed ID: 30798995
    [No Abstract] [Full Text] [Related]

  • 14. Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.
    Fakhouri F, Hourmant M, Campistol JM, Cataland SR, Espinosa M, Gaber AO, Menne J, Minetti EE, Provôt F, Rondeau E, Ruggenenti P, Weekers LE, Ogawa M, Bedrosian CL, Legendre CM.
    Am J Kidney Dis; 2016 Jul; 68(1):84-93. PubMed ID: 27012908
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Case Report: Variable Pharmacokinetic Profile of Eculizumab in an aHUS Patient.
    Bouwmeester RN, Ter Avest M, Wijnsma KL, Duineveld C, Ter Heine R, Volokhina EB, Van Den Heuvel LPWJ, Wetzels JFM, van de Kar NCAJ.
    Front Immunol; 2020 Jul; 11():612706. PubMed ID: 33519821
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome: an update.
    Ardissino G, Tel F, Sgarbanti M, Cresseri D, Giussani A, Griffini S, Grovetto E, Possenti I, Perrone M, Testa S, Paglialonga F, Messa P, Cugno M.
    Pediatr Nephrol; 2018 Mar; 33(3):457-461. PubMed ID: 29046944
    [Abstract] [Full Text] [Related]

  • 20. Eculizumab treatment in atypical hemolytic uremic syndrome: correlation between functional complement tests and drug levels.
    Cugno M, Capone V, Griffini S, Grovetti E, Pintarelli G, Porcaro L, Clementi E, Ardissino G.
    J Nephrol; 2022 May; 35(4):1205-1211. PubMed ID: 35013983
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.